471,993 Shares in Kura Oncology, Inc. $KURA Acquired by Fisher Asset Management LLC

Fisher Asset Management LLC bought a new position in Kura Oncology, Inc. (NASDAQ:KURA) in the fourth quarter, Holdings Channel reports. The institutional investor bought 471,993 shares of the company’s stock, valued at approximately $4,904,000.

A number of other hedge funds also recently bought and sold shares of KURA. Jacobs Levy Equity Management Inc. lifted its position in Kura Oncology by 101.6% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock worth $19,688,000 after buying an additional 1,121,228 shares during the last quarter. Qube Research & Technologies Ltd lifted its position in Kura Oncology by 63.0% in the 2nd quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock worth $11,032,000 after buying an additional 738,761 shares during the last quarter. Nan Fung Trinity HK Ltd. lifted its position in Kura Oncology by 317.9% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 964,880 shares of the company’s stock worth $10,025,000 after buying an additional 734,000 shares during the last quarter. UBS Group AG lifted its position in Kura Oncology by 118.3% in the 4th quarter. UBS Group AG now owns 1,060,025 shares of the company’s stock worth $11,014,000 after buying an additional 574,455 shares during the last quarter. Finally, Man Group plc lifted its position in Kura Oncology by 234.7% in the 2nd quarter. Man Group plc now owns 522,388 shares of the company’s stock worth $3,014,000 after buying an additional 366,324 shares during the last quarter.

Kura Oncology Stock Performance

Shares of KURA stock opened at $9.97 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.14 and a current ratio of 6.15. Kura Oncology, Inc. has a fifty-two week low of $5.45 and a fifty-two week high of $12.49. The stock has a 50 day moving average price of $9.15 and a two-hundred day moving average price of $9.47. The company has a market capitalization of $885.04 million, a P/E ratio of -2.98 and a beta of 0.32.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The firm had revenue of $18.27 million during the quarter, compared to the consensus estimate of $25.97 million. Analysts expect that Kura Oncology, Inc. will post -3.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

KURA has been the subject of a number of recent research reports. Mizuho dropped their target price on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, March 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a research report on Tuesday, April 21st. UBS Group restated a “buy” rating and issued a $15.00 target price (down from $16.00) on shares of Kura Oncology in a research report on Friday, March 13th. Jefferies Financial Group set a $24.00 target price on Kura Oncology in a research report on Thursday. Finally, Oppenheimer set a $24.00 price objective on Kura Oncology in a research report on Thursday. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Kura Oncology currently has an average rating of “Moderate Buy” and a consensus price target of $25.90.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.